Optimal first-line immunotherapy duration in metastatic NSCLC with controlled disease remains unclear. We evaluated 6-month nivolumab-ipilimumab (Nivo-Ipi) in patients with disease control (DC).
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 12 Feb 2026.
The item focuses on Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 “DICIPLE” Phase III Trial.
Review the original article for the full source wording and details.